JERUSALEM (Reuters) - Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round. Nvidia, Pfizer, Thermo Fisher and venture capital investor OurCrowd participated in the round, CytoReason said. The company said it aims to expand the application of its models into additional indications and grow its proprietary molecular and clinical data. It also plans to establish an office in Cambridge, Massachusetts, later this year. In 2022, Pfizer expanded its partnership with CytoReason with a $20 million investment that could reach $110 million by 2027. "The rapid expansion of new technologies, like artificial intelligence, holds tremendous potential to help transform what is possible in human health," said Mikael Dolsten, Pfizer's chief scientific officer. "Our collaboration with CytoReason leverages its cutting-edge immunology multiomics platform to augment Pfizer’s own R&D capabilities and generate invaluable insights into new drug development pathways for patients." CytoReason said six of the world’s top 10 pharma companies use its technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism, and other therapeutic areas using an AI platform of computational disease models. (Reporting by Steven Scheer; editing by Jason Neely)
Nvidia, Pfizer lead $80 million funding for Israeli medical AI tech firm CytoReason
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...